- Home
- USB vs GSK Comparison
USB vs GSK Comparison
Compare USB & GSK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | USB | GSK |
|---|---|---|
| Founded | 1863 | 1715 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 86.3B | 96.1B |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | USB | GSK |
|---|---|---|
| Price | $56.07 | $50.36 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 20 | 2 |
| Target Price | ★ $57.45 | N/A |
| AVG Volume (30 Days) | ★ 10.8M | 4.2M |
| Earning Date | 01-20-2026 | 02-04-2026 |
| Dividend Yield | ★ 3.75% | 3.41% |
| EPS Growth | 21.97 | ★ 118.57 |
| EPS | ★ 4.62 | 1.79 |
| Revenue | $26,354,000,000.00 | ★ $43,237,357,842.00 |
| Revenue This Year | $14.70 | $6.70 |
| Revenue Next Year | $4.67 | $5.10 |
| P/E Ratio | ★ $12.01 | $27.52 |
| Revenue Growth | ★ 5.01 | 2.73 |
| 52 Week Low | $35.18 | $32.38 |
| 52 Week High | $56.70 | $51.46 |
Technical Indicators
Market Signals| Indicator | USB | GSK |
|---|---|---|
| Relative Strength Index (RSI) | 62.18 | 58.41 |
| Support Level | $55.28 | $47.62 |
| Resistance Level | $56.70 | $50.87 |
| Average True Range (ATR) | 1.00 | 0.80 |
| MACD | -0.03 | -0.11 |
| Stochastic Oscillator | 81.22 | 70.31 |
Price Performance
Historical ComparisonAbout USB U.S. Bancorp
With assets of around $695 billion, U.S. Bancorp is one of the largest regional banks in the US with its footprint in 26 states. The bank's branch network is mostly in Midwestern and Western markets. U.S. Bancorp has a comprehensive product set, with offerings in retail and commercial banking, credit cards, mortgages, payment services, trust, and wealth services.
About GSK GSK plc (Each representing two)
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, antiviral, and vaccines, and has been growing its presence in oncology and immunology, as well. GSK uses joint ventures to gain additional scale in certain markets like HIV.